Waltham, MA, July 22, 2026 (Reuters) -- Repligen has agreed to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion. The acquisition expands Repligen’s portfolio of bioprocessing technologies and strengthens its capabilities in supporting cell and gene therapy manufacturing. The deal is expected to enhance the company’s offerings for biopharmaceutical customers and support its long-term growth strategy. Read full article here.

Indianapolis, IN, July 20, 2026 (PR Newswire) -- Roche Diagnostics North America has appointed Dan Malarek as president and chief executive officer. Malarek will lead the company’s North American diagnostics business, overseeing commercial strategy, operations, and continued innovation across its portfolio. The leadership appointment is intended to strengthen Roche’s position in the region and support future growth in diagnostic solutions. Read full article here.

Tempe, AZ, June 9, 2026 (PR Newswire) -- GT Medical Technologies has completed an oversubscribed $100 million Series E equity financing to support commercialization of its treatment for patients with operable brain tumors. The proceeds will be used to expand market adoption, scale manufacturing, and advance additional clinical and commercial initiatives. The financing strengthens the company's position as it broadens access to its targeted radiation therapy platform. Read f

Cambridge, MA, July 27, 2026 (Business Wire) -- Sarepta Therapeutics has appointed Michael F. Severino as chief executive officer. Severino will lead the company’s strategic direction as it advances its portfolio of genetic medicines and commercial operations. The leadership appointment is intended to strengthen execution across Sarepta’s pipeline and support its next phase of growth. Read full article here.

Indianapolis and New York, July 16, 2026 (PR Newswire) -- Eli Lilly and Company has agreed to acquire Atai Beckley in a deal worth up to $1.6 billion. The acquisition is intended to strengthen Lilly’s pipeline of therapies for treatment-resistant depression and other mental health disorders by adding novel neuropsychiatric programs. The transaction supports Lilly’s strategy to expand its neuroscience portfolio with innovative treatments for patients with significant unmet n

Stockholm, Sweden, July 7, 2026 (EQT) -- EQT has agreed to acquire the TachoSil biosurgery business from Corza Medical. The transaction will establish TachoSil as an independent company focused on advancing its surgical sealant portfolio and expanding its global market presence. EQT plans to support the business through continued investment in commercial growth, product innovation, and strategic expansion. Read full article here.

San Diego, CA, July 7, 2026 (Globe Newswire) -- ARS Pharmaceuticals has announced a CEO succession plan, with Richard Lowenthal assuming the role of chief executive officer. The leadership transition is designed to support the company’s continued commercial growth and strategic priorities. ARS Pharmaceuticals expects the change to provide continuity as it advances its product portfolio and long-term expansion plans. Read full article here.

Basel, Switzerland, July 6, 2026 (Novartis) -- Novartis has agreed to acquire Myricx Bio in a deal valued at up to $2.9 billion. The acquisition adds Myricx Bio’s next-generation antibody-drug conjugate (ADC) technology, including its novel NMTi payload platform, to strengthen Novartis’ oncology pipeline. The transaction is intended to broaden treatment options for cancer patients and reinforce Novartis’ position in targeted cancer therapies. Read full article here.

New Orleans, LA, July 14, 2026 (PR Newswire) -- ARK Surgical has appointed Joseph B. Labruzzo to its board of directors and as president and chief executive officer of its U.S. operations. Labruzzo will lead the company’s commercial strategy and operational expansion in the United States as ARK Surgical broadens its market presence. The leadership appointment is intended to support the company’s next phase of growth and accelerate adoption of its surgical technologies. Read

Boston, MA, July 12, 2026 (Yahoo Finance) -- Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in a transaction valued at approximately $10 billion. The acquisition strengthens Vertex’s endocrinology pipeline by adding Crinetics’ portfolio of therapies for endocrine disorders, including late-stage programs. The deal supports Vertex’s strategy to diversify its portfolio beyond rare diseases and expand its presence in endocrine medicine. Read full article

San Diego, CA, June 24, 2026 (Business Wire) -- Ollin Biosciences has secured $330 million in an oversubscribed Series B financing round to support global Phase 3 development of OLN324. The funding will be used to advance studies in diabetic macular edema (DME) and wet age-related macular degeneration (AMD), with trials scheduled to begin in the second half of 2026. The financing strengthens the company’s resources as it moves its lead ophthalmology candidate into late-stag

Franklin Lakes, NJ, July 1, 2026 (Drug Delivery Business) -- BD has named Brian Thompson as president of its Pharmacy Automation business. Thompson will lead the division’s strategy and operations as BD seeks to expand its medication management and automation capabilities. The appointment is aimed at supporting growth and advancing innovation across the company’s pharmacy technology portfolio. Read full article here.

North Chicago, IL, June 22, 2026 (PR Newswire) -- AbbVie has agreed to acquire Apogee Therapeutics in a transaction valued at approximately $1.8 billion. The acquisition adds promising immunology programs that complement AbbVie’s existing portfolio and strengthen its pipeline in immune-mediated diseases. The deal is intended to enhance AbbVie’s long-term growth strategy and expand its capabilities in next-generation immunology therapies. Read full article here.

Cambridge, MA, June 29, 2026 (Business Wire) -- Pixee Medical has named Kristoff Goson as chief executive officer to lead its next phase of growth in the United States. Goson will oversee the company’s strategy to expand commercialization of its orthopedic navigation technologies and strengthen its presence in the U.S. market. The appointment reflects Pixee Medical’s focus on scaling operations and driving broader adoption of its digital surgery solutions. Read full article

Darmstadt, Germany, June 25, 2026 (PR Newswire) -- Merck KGaA has agreed to acquire Bio-Techne in a transaction valued at approximately $17 billion. The acquisition is intended to strengthen Merck’s position in rapidly growing life sciences markets by adding complementary technologies and capabilities. The deal supports the company’s strategy to expand its global presence and enhance its portfolio of research and bioprocessing solutions. Read full article here.

Wilmington, NC, June 8, 2026 (Reuters) -- Incyte has struck a collaboration agreement valued at up to $2 billion with a subsidiary of Star Therapeutics. The deal is structured around upfront funding and milestone-based payments tied to development progress. It is aimed at broadening Incyte’s pipeline with new therapeutic candidates and strengthening its long-term growth strategy. Read full article here.

Gaithersburg, MD, June 16, 2026 (Business Wire) -- GeneDx has named Mark Gardner as its new president. The appointment is intended to support the company’s next phase of scaling its genomics and precision diagnostics business. GeneDx aims to accelerate operational growth and expand its market reach under the new leadership. Read full article here.

Bedford, MA, June 9, 2026 (Novanta) -- Novanta has announced the acquisition of Riverpoint Medical to strengthen its healthcare and surgical solutions portfolio. The transaction expands Novanta’s capabilities in serving medical device customers with specialized technologies. The acquisition supports the company’s strategy to broaden its offerings and accelerate long-term growth in healthcare markets. Read full article here.

New Britain, PA, June 15, 2026 (PR.com) -- Thrombolex has appointed Michael Tutera as chief executive officer following a planned leadership transition. Co-founder and former CEO Mike Cerminaro will remain involved as a member of the board of directors. The company expects Tutera’s commercial and operational experience to support broader adoption of its endovascular catheter platform and drive the next stage of growth. Read full article here.

London, June 9, 2026 (GSK) -- GSK has entered an agreement to acquire Nuvalent in a transaction valued at $10.6 billion. The acquisition adds late-stage targeted oncology assets focused on lung cancer and expands GSK’s precision medicine capabilities. The deal is intended to accelerate growth in oncology and strengthen the company’s long-term pipeline strategy. Read full article here.